Such strategies, or ‘liquid biopsies’, already have value in lung neoplasia, e.g. for monitoring treatment responses to epidermal growth factor receptor (EGFR) inhibitors through identification of mutation T790M in circulating tumour DNA [5], and are becoming standards of care [6, 7]. This evidence concerns the gene EGFR and neoplasm.